Propionate inhibits oxygen consumption by rat liver mitochonria when elutamate, a-ketaglutarate, and succinate are subitrates. ~a r n i t i n e prevents thiseffect. The pattern of inhibition of 4 C 0 2 release from metabolic intermediates indicates citric acid :ycle inhibition between succinate:coenzyme A (CoA) ligase :GDP) and malate dehydrogenase. Propionyl CoA is synthesized Tom propionate in mitochondria. Propionyl CoA is a potent nhibitor of succinate:CoA ligase with positive cooperativity and ialf-maximal inhibition at 2 X lo-' M propionyl CoA.
( p H 7.4). Thioester concentration was followed at 235 nm with a Beckman model 25 recording spectrophotometer at 30°C' during the initial several min when linearity with time was observed. Enzyme concentration was adjusted to maintain initial rates of less than 0.04 A units/min. The reaction was initiated by addition ofenryme after a stable, llat baseline was obtained. The difference of molar absorptivities between succinyl C'oA and C'oA under these conditions is 4.0 mM cm (4) . Purified pig heart succinate: C'oA ligase (SCL) was purchased from Sigma Chemical ('0. for use in the kinetic analyses. Statistical and Michaelis-Menton enxyme kinetic analyses match those used previously (29). Hill plots (7) were evaluated by linear regression analysis. Proplon~c acid was neutralized with NaOH or KOH before use in all these experiments.
Propionate inhibited state 3 rates and slightly stimulated state u 2 4 rates of oxygen consumption (Table I ) . Both these effects contributed to a decreased respiratory control ratio ( R C R ) ( Table  2 ). These effects were observed with glutamate. tr-ketoglutarate. and succinate. There was no alteration of ADP:O ratios, despite the reduced RCR (Table 2) . Carnitine. when preincubated with propionate. prevented or minimi~ed these effects of propionate. This carnitine effect was variable and sometimes only seen at lower propionate concentrations. Carnitine did not reverse the effects of propionate in the short time (about I min) available after assessing the primary effect of propionate. These effects of propionate are illustrated in a representative set of experiments (Fig. I ) . Propionate effects on other substrates suitable for polarogr&hic assays. including pyruvate:malate and palmitylcarnitine. METHODS could not be as accurately assessed because of the poor RCR's that occurred in control runs after the 5 min preincubation. Mitochondria were prepared from rat liver and polarographic Preincubation of mitochondria with propionate was necessary assays performed as previously described (27) . Propionate was for consistent. maximal inhibition of state 3 rates. Following a preincubated with mitochondria for 4.5 min at 30°C before ad-preincubation of mitochondria and maximal inhibition of state 3 dition ol'olher reagents; controls were preil~cubalecl withoul pro-rates, xubscqucntly a J J c J 1lli1~1ctlc)ndria a r c not ir~irlicdii~tcly i~f -pionate. A final propionate concentration of 4.76 mM was used in fected. There was a variation in the susceptibility of mitochondria. standard assays. I4C-Labeled compounds were added (final con-The relatively high propionate concentration was used because all centration, 3.3 mM) after preincubation as above with additional preparations were affected at this level. Some mitochondrial prepincubation at 30°C for 15 min and "COL. collection ah previously arations were affected at propionate concentrations as low as 0.4 reported (28) 
' Numbers In parenthe\e\, n ' Slgn~ficantly le\s than control. I test (palred \amples). P < 0 01
' S~gn~ficantly greater than control, r te\t (palred sample\). P < 0 05 Table 2 Effect of propronare on oxrdatrve pho~phorvlarron
Prop~onate (4 76 mM) Control ~r o~~o n a t e ' (4 76 mM) [4 6-6 51
' Numbers in parentheses, n.
P < 0.005 by Mann-Whitney (Wllcoxin) statistic. " Numbers in brackets, range.
" Unable to evaluate because of poor state 3 -4 transition propionyl CoA concentrations, this plot was concave upward, indicating a different mechanism of inhibition. The Dixon plot (i versus I/v) was also nonlinear (Fig. 2) . The Hill plots were linear ( Fig. 3) with a Hill coeficient ( n ) of 3.29 rt 0.26 (mean f S.E.: 6 determinat~ons) and hall-maximal inhibition at 246 f 27 pM v (calculated from log --= 0 intercept). Propionic acid and V,, -V, propionyl CoA were not substrates for the enzyme when added to the reaction mixture in place of succinate or succinyl CoA, nor did propionate affect enzyme activity. Typical Michaelis-Menton kinetics were obtained in the absence of propionyl CoA with a succinyl CoA K,, of 23 pM and succinate K,,, of 313 pM in the forward and reserve reactions, respectively.
Several other acyl CoA derivatives were evaluated for similar effects on SCL. These limited experiments, one or 2 Hill plots per compound. are included for completeness (Table 4) but must be viewed with caution until more extensive investigations are available.
DISCUSSION
Propionyl CoA inhibition of SCL may explain the impaired oxidative metabolism produced by propionate. Many features of propionic acidemia may relate to this effect. Levels of this inhibitor are probably reduced by carnitine in vitro, suggesting a clinical therapeutic modality.
Maximal effects occur with preincubation. implying inhibition by a metabolic product or depletion of vital compounds. Inhibitor is in the matrix rather than the incubation media because subsequently added mitochondria are unaffected. Addition of propionate to mitochondria increases propionyl CoA and reduces free CoA and acetyl CoA (25) . Propionyl CoA is an inhibitor of SCL with positive cooperativ ity. The Hill coefficient suggests 4 propionyl CoA-binding site: per mole of enzyme. Cooperativity can be due to allosteric inter actions or. particularly with multisubstrate enzymes. to othe mechanisms (7) . No allosteric regulation was recognized in othe studies, but they did not include propionyl CoA (17) .
Other acyl CoA derivates are approximately equipollent i~ inhibiting SCL. The concentrations required are similar to thosc affecting pyruvate carboxylase (EC 6.4.1.1) (24) . succinyl CoA:3 oxoacid transferase (EC 2.8.3.5) (6). carbamylphosphate synthe tase (9) . and the glycine cleavage system (15).
Free CoA also affects SCL. Hill coefficients and half-maxima inhibition concentrations are such that at low concentrations Cok has a modest effect, and propionyl CoA is without effect. A higher concentrations, propionyl CoA is a more potent inhibito than an equivalent amount of CoA. Thus. if total CoA (free plu propionyl) is constant and the effects are additive. SCL is inhibitec as the proportion of CoA in the propionyl CoA form is increased High acyl CoA levels may regulate citric acid cycle flux. Positivi cooperativity optimizes regulatory potential by providing , "chemical switch" that turns off an enzyme at a critical inhibito concentration. In patients with organic acidemias. this can resul in catastrophic effects when high acyl CoA levels are the result o their metabolic block rather than reflecting their overall metaboli status.
Propionyl CoA inhibits the PDHC (2). and propionate inhibit state 3 rates of oxygen consumption with pyruvate as substrat (34) . This oxygen consumption depends not only on NADI generated by the PDHC but. to a large degree. on subsequen 1 1 2 9 ergy deficiency state (30) or the inhibition of carbamylphosphate synthetase by propionyl CoA (9) . Impaired flux through the citric acid cycle might contribute to the lactic acidosis and ketosis because catabolism of these compounds requires the citric acid cycle. oxidative reactions in the citric acid cycle. We observed n o effect on [I-"CJpyruvate decarboxylation although we used concentrations of propionate sufficient to inhibit oxy en consumption with 8 pyruvate (34) . Also, decarboxylation of [2-' Clpyruvate via acetyl CoA was not affected. indicating that reduced oxygen consumption is not due to depletion of CoA or inhibition of the PDHC.
Serum propionate levels reach 5 mM in propionic acidemia ( 2 1). Infusion of propionate at this concentration produces tissue levels of about 50 pM propionyl CoA (20. 25). Mitochondria1 levels are probably higher. particularly in the human disorder where propionate is derived from mitochondria1 propionyl CoA. Concentrations used in our studies approximate those encountered in clinical situations.
Inhibition of the citric acid cycle would impair energy generation and the catabolism of many substrates. Propionate inhibits ureagenesis ( 8 ) . and hyperammonemia might result from an en- ' Numbers in parentheses, n Hyperglycinemia in propionic acidemia may result from inhibition of the glycine cleavage system ( I 1, 31). Alternatively. acyl CoA derivatives may affect the succinate-glycine cycle. This proposed cycle remains poorly defined. 8-Aminolevulinic acid synthetase initiates the cycle: succinyl CoA and glycine condense. releasing COa. Subsequent reactions form y.8-dioxovaleric acid and a-ketoglutaraldehyde (14. 19) . It is not clear whether succinyl CoA is reformed from succinate (via SCL) or from u-ketoglutarate (via its dehydrogenase). If the former is the case. then our results may provide an explanation for the hyperglycinemia in propionic acidemia. Our results may also have significance to patients with acute intermittent porphyria because crises are related to increased 6-aminolevulinic acid synthetase activity and changes in y,6-dioxovalerate excretion (14) .
Fatty liver in propionic acidemia indicates impaired catabolism of fatty acids. Inhibition of palmitate decarboxylation in our study did not reach statistical significance. but did in another investigation (8). Low concentrations of propionate (0.5 mM) reduced acetyl CoA and acetyl carnitine formation apparently by inhibiting fatty acid activation or /I-oxidation because propionate does not inhibit acetyl CoA synthetase (EC 6.2.1.1). deplete available carnitine. or accelerate acetyl CoA removal by citrate synthase (EC 4.1.3.7) at these low concentrations (20) . Activation bf fatty acids occurs by three mechanisms. High propionate concentrations may impair activation outside the matrix to a carnitine derivative --by sequestering carnitine as a propionyl derivative. Activation also occurs in the matrix by either an ATP-or GTP-dependent acyl CoA synthetase (EC 6.2.1.3). The ATP-dependent acyl CoA synthetase produces AMP. and the only mechanism for converting AMP back to ADP in the matrix is by the GTP-AMP transphosphorylase (EC 2.7.4.10) (10) . Therefore, both matrix-activating enzymes rely on GTP. The major sources of matrix GTP are SCL and ATP:nucleosidediphosphate phosphotransferase (EC 2.7.4.6) (16). Thus. oxidation of citric acid cycle substrates and fatty acids are mutually controlled (22) . Inhibition of SCL by propionyl CoA could reduce matrix GTP and fatty acid activation. Low matrix G T P could contribute to the fatty liver in propionic acidemia. Low matrix GTP could also impair gluconeogenesis because the GTP-dependent gluconeogenic enzyme phosphoenolpyruvate carboxykinase (EC 4.1.1.32) is located in the mitochondrial matrix in man.
Propionyl CoA can be readily converted to propionylcarnitine in liver ( I ) . At high propionate concentrations (4 mM in infusates), free carnitine is reduced to 10% of control in liver (20) . This might account for the protective effect of added carnitine in our system. This observation might be relevant to the treatment of patients with propionic acidemia. Carnitine has been administered safely in other clinical situations ( 13.23) and might ameliorate symptoms in propionic acidemia by reducing levels of toxic propionyl CoA.
Carnitine may prevent the adverse metabolic effects of othe organic acids (3. 12) .
Our results may be important to other organic acid disorder including methylmalonic aciduria. /I-ketothiolase deficiency, anc glutaric aciduria. Also. levels of short-and medium-chain organil acids are significantly elevated in serum of Reye's syndrom~ patients (18. 32. 33). Future studies of these disorders migh include assays of acyl CoA tissue and mitochondrial concentra tions. Direct assay of SCL may not be useful because acyl CotJ derivatives would be diluted in preparing tissues for SCL assay.
